Lyra Therapeutics, Inc.LYRANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-0.1x
Contraction
Streak
4 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | -2.92% |
| 2023 | 8.55% |
| 2022 | 23.58% |
| 2021 | 46.65% |
| 2020 | 115.89% |
| 2019 | 27.18% |
| 2018 | 0.00% |